Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech 10-K can feel like decoding a lab notebook—especially when Keros Therapeutics packs pages with TGF-β science, trial cohorts, and burn-rate math. If you have ever asked, “Keros Therapeutics SEC filings explained simply,” you are not alone.
Stock Titan pairs each document with AI-powered clarity. Our platform flags dose-response data buried in a Keros Therapeutics annual report 10-K simplified, highlights cash-runway updates inside every Keros Therapeutics quarterly earnings report 10-Q filing, and streams Keros Therapeutics Form 4 insider transactions real-time so you can spot executive confidence the moment it is disclosed. Whether you need the latest Keros Therapeutics 8-K material events explained or plan to scrutinize the Keros Therapeutics proxy statement executive compensation, the information arrives seconds after EDGAR posts—already summarized.
Here is how professionals put it to work:
- Monitor Keros Therapeutics insider trading Form 4 transactions to gauge management sentiment.
- Compare enrollment progress across trials using our Keros Therapeutics earnings report filing analysis.
- Quickly surface option grants through Keros Therapeutics executive stock transactions Form 4.
- Save hours understanding Keros Therapeutics SEC documents with AI instead of parsing PDF tables line by line.
All filing types—10-K, 10-Q, 8-K, S-3, DEF 14A—arrive with real-time alerts, plain-language summaries, and cross-links to earlier disclosures. Complex science meets practical insight, so you can focus on valuation, not vocabulary.
ADAR1 Capital Management and related entities report beneficial ownership of 5,389,264 shares (13.27%) of Keros Therapeutics (KROS). The Schedule 13D/A (Amendment No.4) states ADAR1 issued an August 21, 2025 press release and open letter criticizing the Board's refusal to engage on strategy, capital allocation and Board refreshment and said it will seek to elect new directors at the next annual meeting if the Board continues to refuse engagement. The filing notes no transactions in the past 60 days, the reporting persons no longer hold previously reported long and short put positions, and the ownership percentage is based on 40,615,414 shares outstanding as of July 31, 2025.
Keros Therapeutics insider Lorena Raquel Lerner, identified as the company’s Chief Science Officer, reports beneficial ownership of 35,000 restricted stock units and employee stock options covering 41,379 underlying shares. The RSUs vest in three tranches (33% on Feb 17, 2026; 34% on Aug 15, 2026; 33% on Feb 16, 2027). Listed options have exercise prices of $43.99, $54.38 and $56.18 with multi-year vesting schedules.
Esther Cho, SVP and General Counsel of Keros Therapeutics, Inc. (KROS), reported initial beneficial ownership on Form 3 for an event dated 08/06/2025. She directly holds 44,000 shares (RSUs) and beneficially owns employee stock options exercisable into 165,968 common shares across five option grants with exercise prices ranging from $29.02 to $70.93.
ADAR1 Capital Management LLC and related entities reported significant trading activity in Keros Therapeutics (KROS) securities on June 20, 2025. The transactions involved both direct stock sales and put option exercises:
- ADAR1 Partners LP disposed of 1,500 shares of common stock: - 100 shares at $60 per share - 1,400 shares at $70 per share
- Spearhead Insurance Solutions IDF LLC disposed of 200 shares at $70 per share
- Related put options were exercised, corresponding to the stock dispositions: - One $60 strike put option for 100 shares - Sixteen $70 strike put options for 1,600 shares total
Following these transactions, ADAR1 Partners LP maintains beneficial ownership of 4,391,237 shares, while Spearhead Insurance Solutions holds 743,358 shares. All reporting persons are considered 10% owners of Keros Therapeutics, with Daniel Schneeberger serving as the manager of the related entities.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
